Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Review Series - Recent Advances in the Management of Secondary Hypertension
  • Published:

Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension

Hypertension Research volume 43, pages 744–753 (2020)Cite this article

Abstract

Resistant hypertension is associated with a poor prognosis due to organ damage caused by prolonged suboptimal blood pressure control. The concomitant use of mineralocorticoid receptor (MR) antagonists with other antihypertensives has been shown to improve blood pressure control in some patients with resistant hypertension, and such patients are considered to have MR-associated hypertension. MR-associated hypertension is classified into two subtypes: one with a high plasma aldosterone level, which includes primary aldosteronism (PA), and the other with a normal aldosterone level. In patients with unilateral PA, adrenalectomy may be the first-choice procedure, while in patients with bilateral PA, MR antagonists are selected. In addition, in patients with other types of MR-associated hypertension with high aldosterone levels, MR antagonists may be selected as a first-line therapy. In patients with normal aldosterone levels, ARBs or ACE inhibitors are used as a first-line therapy, and MR antagonists may be used as an add-on agent. Since MR antagonist therapy may have efficacy as a first-line or add-on agent in these patients, it is important to recognize this type of hypertension. Further studies are needed to elucidate the pathogenesis and management of MR-associated hypertension in more detail to improve the clinical outcomes of patients with MR-associated hypertension.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007;5:e012.

    PubMed  PubMed Central  Google Scholar 

  2. Funder JW. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology. 2006;147:5564–7.

    CAS  PubMed  Google Scholar 

  3. Conn JW. Primary aldosteronism. J Lab Clin Med. 1955;45:661–4.

    CAS  PubMed  Google Scholar 

  4. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045–50.

    CAS  PubMed  Google Scholar 

  5. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–916.

    CAS  PubMed  Google Scholar 

  6. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.

    PubMed  Google Scholar 

  7. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–20.

    PubMed  Google Scholar 

  8. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41–50.

    CAS  PubMed  Google Scholar 

  9. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab. 2009;94:1191–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, Takeda Y, et al. High prevalence of diabetes in patients with primary aldosteronism (pa) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: a large, multicenter cohort study in Japan. Diabetes Care. 2019;42:938–45.

    CAS  PubMed  Google Scholar 

  11. Velema M, Dekkers T, Hermus A, Timmers H, Lenders J, Groenewoud H, et al. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment. J Clin Endocrinol Metab. 2018;103:16–24.

    PubMed  Google Scholar 

  12. Reincke M. Anxiety, depression, and impaired quality of life in primary aldosteronism: why we shouldn’t ignore it! J Clin Endocrinol Metab. 2018;103:1–4.

    PubMed  Google Scholar 

  13. Rocha R, Stier CT Jr., Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871–8.

    CAS  PubMed  Google Scholar 

  14. El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension. 2001;37:845–50.

    CAS  PubMed  Google Scholar 

  15. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci. 2002;970:89–100.

    CAS  PubMed  Google Scholar 

  16. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791–800.

    CAS  PubMed  Google Scholar 

  17. Rossi GP, Cesari M, Pessina AC. Left ventricular changes in primary aldosteronism. Am J Hypertens. 2003;16:96–8.

    PubMed  Google Scholar 

  18. Dartsch T, Fischer R, Gapelyuk A, Weiergraeber M, Ladage D, Schneider T, et al. Aldosterone induces electrical remodeling independent of hypertension. Int J Cardiol. 2013;164:170–8.

    PubMed  Google Scholar 

  19. Rossi GP, Seccia TM, Gallina V, Muiesan ML, Leoni L, Pengo M, et al. Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design. J Hum Hypertens. 2013;27:158–63.

    CAS  PubMed  Google Scholar 

  20. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension. 2008;51:1366–71.

    CAS  PubMed  Google Scholar 

  21. Martinez-Aguayo A, Carvajal CA, Campino C, Aglony M, Bolte L, Garcia H, et al. Primary aldosteronism and its impact on the generation of arterial hypertension, endothelial injury and oxidative stress. J Pediatr Endocrinol Metab. 2010;23:323–30.

    CAS  PubMed  Google Scholar 

  22. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594–7.

    CAS  PubMed  Google Scholar 

  23. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308–14.

    CAS  PubMed  Google Scholar 

  24. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802–10.

    CAS  PubMed  Google Scholar 

  25. Takeda Y. Role of cardiovascular aldosterone in hypertension. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:261–6.

    CAS  PubMed  Google Scholar 

  26. Yugar-Toledo JC, Bonalume Tacito LH, Ferreira-Melo SE, Sousa W, Consolin-Colombo F, Irigoyen MC, et al. Low-renin (volume dependent) mild-hypertensive patients have impaired flow-mediated and glyceryl-trinitrate stimulated vascular reactivity. Circ J. 2005;69:1380–5.

    CAS  PubMed  Google Scholar 

  27. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47:312–8.

    CAS  PubMed  Google Scholar 

  28. Ruilope LM. Aldosterone, hypertension, and cardiovascular disease: an endless story. Hypertension. 2008;52:207–8.

    CAS  PubMed  Google Scholar 

  29. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.

    CAS  PubMed  Google Scholar 

  30. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.

    CAS  PubMed  Google Scholar 

  31. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.

    CAS  PubMed  Google Scholar 

  32. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol. 2001;88:906–9, A8.

    CAS  PubMed  Google Scholar 

  33. Chung YW, Yang YH, Wu CK, Yu CC, Juang JM, Wang YC, et al. Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy. Int J Cardiol. 2016;202:962–6.

    PubMed  Google Scholar 

  34. Simopoulos V, Tagarakis G, Hatziefthimiou A, Skoularigis I, Triposkiadis F, Trantou V, et al. Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study. Clin Res Cardiol. 2015;104:31–7.

    CAS  PubMed  Google Scholar 

  35. Wei J, Ni J, Huang D, Chen M, Yan S, Peng Y. The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis. Clin Cardiol. 2010;33:572–7.

    PubMed  PubMed Central  Google Scholar 

  36. Beygui F, Labbe JP, Cayla G, Ennezat PV, Motreff P, Roubille F, et al. Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. Int J Cardiol. 2013;167:73–9.

    PubMed  Google Scholar 

  37. Bolignano D, Palmer SC, Navaneethan SD, and Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004.

    Google Scholar 

  38. Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17:127.

    PubMed  PubMed Central  Google Scholar 

  39. Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Resistant hypertension. BMJ. 2012;345:e7473.

    PubMed  Google Scholar 

  40. Williams B. Resistant hypertension: an unmet treatment need. Lancet. 2009;374:1396–8.

    PubMed  Google Scholar 

  41. Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015;28:1376–85.

    CAS  PubMed  Google Scholar 

  42. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–30.

    CAS  PubMed  Google Scholar 

  43. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514–23.

    CAS  PubMed  Google Scholar 

  45. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 2011;79:1051–60.

    CAS  PubMed  Google Scholar 

  46. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens. 2003;16:781–8.

    CAS  PubMed  Google Scholar 

  47. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart. 1999;82:57–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Horita Y, Taura K, Taguchi T, Furusu A, Kohno S. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology. 2006;11:462–6.

    CAS  PubMed  Google Scholar 

  49. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29:13–21.

    CAS  PubMed  Google Scholar 

  50. Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zeni P, et al. Relation of aldosterone “escape” despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;89:403–7.

    CAS  PubMed  Google Scholar 

  51. Narayan H, Webb DJ. New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. Curr Hypertens Rep. 2016;18:34.

    PubMed  PubMed Central  Google Scholar 

  52. Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res. 2006;29:211–6.

    CAS  PubMed  Google Scholar 

  53. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens. 2004;22:863–9.

    CAS  PubMed  Google Scholar 

  54. Racine MC, Douville P, Lebel M. Functional tests for primary aldosteronism: value of captopril suppression. Curr Hypertens Rep. 2002;4:245–9.

    PubMed  Google Scholar 

  55. Sartori M, Calo LA, Mascagna V, Realdi A, Macchini L, Ciccariello L, et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens. 2006;19:373–9.

    CAS  PubMed  Google Scholar 

  56. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA. 2003;100:14211–6.

    CAS  PubMed  Google Scholar 

  57. Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fat Acids. 1999;60:401–5.

    CAS  Google Scholar 

  58. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356–62.

    CAS  PubMed  Google Scholar 

  59. Harada E, Mizuno Y, Katoh D, Kashiwagi Y, Morita S, Nakayama Y, et al. Increased urinary aldosterone excretion is associated with subcutaneous not visceral, adipose tissue area in obese individuals: a possible manifestation of dysfunctional subcutaneous adipose tissue. Clin Endocrinol. 2013;79:510–6.

    CAS  Google Scholar 

  60. Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation. 2015;132:2134–45.

    CAS  PubMed  Google Scholar 

  61. Krug AW, Vleugels K, Schinner S, Lamounier-Zepter V, Ziegler CG, Bornstein SR, et al. Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells. Int J Obes. 2007;31:1605–16.

    CAS  Google Scholar 

  62. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58:811–7.

    CAS  PubMed  Google Scholar 

  63. Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwinski P, Bielen P, Klisiewicz A, et al. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens. 2013;27:678–85.

    CAS  PubMed  Google Scholar 

  64. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19:2271–7.

    CAS  PubMed  Google Scholar 

  65. Martinez-Garcia MA, Navarro-Soriano C, Torres G, Barbe F, Caballero-Eraso C, Lloberes P, et al. Beyond resistant hypertension. Hypertension. 2018;72:618–24.

    CAS  PubMed  Google Scholar 

  66. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010;6:363–8.

    PubMed  PubMed Central  Google Scholar 

  67. Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, Calhoun DA, et al. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens. 2011;29:1553–9.

    CAS  PubMed  Google Scholar 

  68. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24:532–7.

    CAS  PubMed  Google Scholar 

  69. Wolley MJ, Pimenta E, Calhoun D, Gordon RD, Cowley D, Stowasser M. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea. J Hum Hypertens. 2017;31:561–7.

    CAS  PubMed  Google Scholar 

  70. Furlan R, Barbic F, Piazza S, Tinelli M, Seghizzi P, Malliani A. Modifications of cardiac autonomic profile associated with a shift schedule of work. Circulation. 2000;102:1912–6.

    CAS  PubMed  Google Scholar 

  71. Bradley TD, Floras JS. Sleep apnea and heart failure: Part II: central sleep apnea. Circulation. 2003;107:1822–6.

    PubMed  Google Scholar 

  72. Suwazono Y, Dochi M, Sakata K, Okubo Y, Oishi M, Tanaka K, et al. Shift work is a risk factor for increased blood pressure in Japanese men: a 14-year historical cohort study. Hypertension. 2008;52:581–6.

    CAS  PubMed  Google Scholar 

  73. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA. 2009;106:4453–8.

    CAS  PubMed  Google Scholar 

  74. Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: a multitasking molecule. Prog Brain Res. 2010;181:127–51.

    CAS  PubMed  Google Scholar 

  75. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101–10.

    CAS  PubMed  Google Scholar 

  76. Borjigin J, Zhang LS, Calinescu AA. Circadian regulation of pineal gland rhythmicity. Mol Cell Endocrinol. 2012;349:13–9.

    CAS  PubMed  Google Scholar 

  77. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med. 2010;16:67–74.

    CAS  PubMed  Google Scholar 

  78. Grossman E, Messerli FH. Management of blood pressure in patients with diabetes. Am J Hypertens. 2011;24:863–75.

    CAS  PubMed  Google Scholar 

  79. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126:2105–14.

    CAS  PubMed  Google Scholar 

  81. van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285–92.

    PubMed  Google Scholar 

  82. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64–8.

    CAS  PubMed  Google Scholar 

  83. Jansen PM, Danser AH, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27:680–91.

    CAS  PubMed  Google Scholar 

  84. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Investig. 1996;98:1063–8.

    CAS  PubMed  Google Scholar 

  85. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116–23.

    CAS  Google Scholar 

  86. Volk MJ, Bomback AS, Klemmer PJ. Mineralocorticoid receptor blockade in chronic kidney disease. Curr Hypertens Rep. 2011;13:282–8.

    CAS  PubMed  Google Scholar 

  87. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51:199–211.

    PubMed  Google Scholar 

  88. Bomback AS, Toto R. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Am J Hypertens. 2009;22:1032–40.

    CAS  PubMed  Google Scholar 

  89. Toto RD. Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr Opin Nephrol Hypertens. 2010;19:444–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Zulian E, Sartorato P, Benedini S, Baro G, Armanini D, Mantero F, et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Investig. 2005;28:49–53.

    CAS  Google Scholar 

  91. Dona G, Sabbadin C, Fiore C, Bragadin M, Giorgino FL, Ragazzi E, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur J Endocrinol. 2012;166:703–10.

    CAS  PubMed  Google Scholar 

  92. Cascella T, Palomba S, Tauchmanova L, Manguso F, Di Biase S, Labella D, et al. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2006;91:4395–400.

    CAS  PubMed  Google Scholar 

  93. Armanini D, Bordin L, Dona G, Sabbadin C, Bakdounes L, Ragazzi E, et al. Polycystic ovary syndrome: implications of measurement of plasma aldosterone, renin activity and progesterone. Steroids. 2012;77:655–8.

    CAS  PubMed  Google Scholar 

  94. Rafiq K, Hitomi H, Nakano D, Nishiyama A. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. J Pharm Sci. 2011;115:1–7.

    CAS  Google Scholar 

  95. Baker ME, Funder JW, Kattoula SR. Evolution of hormone selectivity in glucocorticoid and mineralocorticoid receptors. J Steroid Biochem Mol Biol. 2013;137:57–70.

    CAS  PubMed  Google Scholar 

  96. Vitellius G, Trabado S, Bouligand J, Delemer B, Lombes M. Pathophysiology of glucocorticoid signaling. Ann Endocrinol. 2018;79:98–106.

    Google Scholar 

  97. Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2019;42:293–300.

    CAS  PubMed  Google Scholar 

  98. Shibata S, Ishizawa K, Uchida S. Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension. Hypertens Res. 2017;40:221–5.

    CAS  PubMed  Google Scholar 

  99. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370–6.

    CAS  PubMed  Google Scholar 

  100. Uddin S, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem. 2000;275:27634–40.

    CAS  PubMed  Google Scholar 

  101. Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Zhu W, et al. Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. Circ Res. 1999;84:458–66.

    CAS  PubMed  Google Scholar 

  102. Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Investig. 2011;121:3233–43.

    CAS  PubMed  Google Scholar 

  103. Nagase M, Ayuzawa N, Kawarazaki W, Ishizawa K, Ueda K, Yoshida S, et al. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1. Hypertension. 2012;59:500–6.

    CAS  PubMed  Google Scholar 

  104. Duncan JL 3rd, Fuhrman GM, Bolton JS, Bowen JD, Richardson WS. Laparoscopic adrenalectomy is superior to an open approach to treat primary hyperaldosteronism. Am Surg. 2000;66:932–5. discussion 935–6

    PubMed  Google Scholar 

  105. Meria P, Kempf BF, Hermieu JF, Plouin PF, Duclos JM. Laparoscopic management of primary hyperaldosteronism: clinical experience with 212 cases. J Urol. 2003;169:32–5.

    PubMed  Google Scholar 

  106. Rossi H, Kim A, Prinz RA. Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. Am Surg. 2002;68:253–6. discussion 256–7

    PubMed  Google Scholar 

  107. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72:658–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  108. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51–9.

    PubMed  Google Scholar 

  109. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018;3:768–74.

    PubMed  PubMed Central  Google Scholar 

  110. Pelliccia F, Patti G, Rosano G, Greco C, Gaudio C. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis. Int J Cardiol. 2014;177:219–28.

    PubMed  Google Scholar 

  111. Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA. Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J Hypertens. 2016;34:11–9.

    CAS  PubMed  Google Scholar 

  112. Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015;761:226–34.

    CAS  PubMed  Google Scholar 

  113. Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020;75:51–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Hypertension, Tokyo Women’s Medical University, Tokyo, Japan

    Satoshi Morimoto & Atsuhiro Ichihara

Authors
  1. Satoshi Morimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atsuhiro Ichihara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Morimoto.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morimoto, S., Ichihara, A. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension. Hypertens Res 43, 744–753 (2020). https://doi.org/10.1038/s41440-020-0468-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-020-0468-3

Keywords

This article is cited by

Search

Advanced search

Quick links